Peptides for Menopause: What Women Over 50 Should Know

Menopause marks the permanent cessation of menstruation, typically occurring between the ages of 45 and 55 in the United Kingdom, with the average age being 51. The transition is driven by the gradual decline and eventual cessation of ovarian oestrogen and progesterone production, fundamentally altering the hormonal landscape of the body.

The consequences of oestrogen decline extend far beyond reproductive function. Oestrogen receptors are found in virtually every tissue in the body, which is why menopause affects such a wide range of systems. Musculoskeletal health declines as oestrogen's protective effects on bone density and joint integrity diminish. Skin quality deteriorates as collagen synthesis slows — women lose approximately 30% of their skin collagen in the first five years after menopause. Cardiovascular risk increases as oestrogen's beneficial effects on lipid profiles and vascular function are lost. Cognitive function and mood can be affected by changes in neurotransmitter activity.

While hormone replacement therapy (HRT) remains the gold-standard medical treatment for menopausal symptoms, some women cannot take HRT due to contraindications (such as a history of hormone-sensitive cancers), and others seek complementary approaches. This has led to growing interest in whether certain peptides might support specific aspects of health during the menopausal transition.

It is essential to emphasise that the peptides discussed in this article are research compounds, not approved treatments for menopause. The evidence presented comes from preclinical and early clinical research, and these peptides should not be viewed as replacements for evidence-based medical care. Any woman experiencing menopausal symptoms should consult her GP or a menopause specialist.

Body Protection Compound 157 (BPC-157) is a synthetic peptide derived from a protective protein found in human gastric juice. It has been extensively studied in animal models for its effects on tissue healing, inflammation, and gastrointestinal protection.

Joint pain and stiffness are among the most common menopausal complaints, affecting up to 50% of women during the transition. The decline in oestrogen reduces synovial fluid production, accelerates cartilage degradation, and promotes inflammatory processes within joints. Preclinical research on BPC-157 has demonstrated its ability to accelerate tendon and ligament healing, reduce inflammatory markers, and promote angiogenesis (the formation of new blood vessels) in damaged tissues. While direct clinical evidence for BPC-157 in menopausal joint symptoms is lacking, the preclinical data on musculoskeletal tissue repair has generated considerable research interest.

Gastrointestinal issues also frequently worsen during menopause, including bloating, altered gut motility, and increased intestinal permeability (sometimes called "leaky gut"). Oestrogen influences gut barrier function and the composition of the gut microbiome, and its decline can contribute to digestive discomfort. BPC-157 has been studied for its cytoprotective effects on the gastrointestinal mucosa, with animal studies demonstrating its ability to accelerate the healing of gastric ulcers, reduce intestinal inflammation, and support gut barrier integrity.

It is important to note that BPC-157 remains a research peptide with no completed large-scale human clinical trials. While the preclinical evidence is promising, its safety profile in postmenopausal women specifically has not been established. Women considering any peptide should discuss it with their healthcare provider in the context of their overall menopausal management plan.

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine. Its concentration in the body declines significantly with age — from approximately 200 ng/mL at age 20 to around 80 ng/mL by age 60 — which has fuelled interest in its potential anti-ageing applications.

The skin changes associated with menopause are among the most visible and distressing for many women. The dramatic decline in oestrogen leads to reduced collagen synthesis, decreased skin thickness, diminished elasticity, and increased dryness. Studies have shown that women can lose up to 2.1% of their skin collagen per year in the postmenopausal period. GHK-Cu has been studied for its ability to stimulate collagen and elastin production, promote glycosaminoglycan synthesis, and enhance the activity of dermal fibroblasts.

Research has also investigated GHK-Cu's role in wound healing and tissue remodelling. Gene expression studies have found that GHK-Cu can upregulate genes associated with collagen production, antioxidant defence, and DNA repair, while downregulating genes linked to inflammation and tissue destruction. In cosmetic applications, topical GHK-Cu formulations have been shown in small clinical studies to improve skin firmness, fine lines, and overall skin quality.

Beyond topical use, some researchers have investigated injectable or systemic GHK-Cu for broader anti-ageing effects, including hair follicle support (relevant to the thinning hair many women experience postmenopausally). However, the evidence base for systemic use is more limited, and GHK-Cu remains primarily a cosmetic and research compound rather than an approved medicine.

Growth hormone (GH) production declines steadily with age — a process termed somatopause. By the time a woman reaches menopause, her GH secretion may be 50–70% lower than during her twenties. This decline is compounded by the loss of oestrogen, which normally enhances GH secretion by modulating hypothalamic GHRH and somatostatin signalling.

The consequences of GH decline include reduced lean muscle mass, increased visceral fat, decreased bone density, impaired recovery from exercise, and changes in sleep quality — all of which overlap significantly with menopausal symptoms. This overlap has led researchers to investigate whether restoring more youthful GH levels might address some aspects of menopausal decline.

CJC-1295 (a synthetic GHRH analogue) combined with ipamorelin (a selective GH secretagogue) has been studied for its ability to stimulate the body's own GH production. The theoretical advantage over exogenous GH injection is that secretagogues work with the body's natural feedback mechanisms, producing pulsatile GH release rather than the continuous elevated levels seen with GH injections. Research suggests this approach may carry a lower risk of side effects such as insulin resistance, joint pain, and fluid retention.

For postmenopausal women specifically, some clinicians in private practice have reported improvements in body composition, sleep quality, recovery from exercise, and skin condition with GH secretagogue protocols. However, it is critical to note that these are clinical observations, not findings from controlled trials in menopausal populations. GH-related therapies also carry theoretical risks including effects on insulin sensitivity and the potential to promote the growth of undetected tumours. Any consideration of GH secretagogues should involve thorough medical evaluation, including screening for contraindications.

Several other peptides have attracted research interest for their potential relevance to specific menopausal concerns.

Selank is a synthetic analogue of tuftsin with anxiolytic and mood-regulating properties. Anxiety and mood disturbances are common during the menopausal transition, driven by oestrogen's influence on serotonin, GABA, and dopamine neurotransmission. Selank has been studied for its ability to modulate GABAergic and serotonergic signalling without the sedation or dependence risk associated with benzodiazepines. While not specifically studied in menopausal populations, its mechanism of action aligns with the neurochemical changes that contribute to perimenopausal anxiety and low mood.

Epitalon (Epithalon) is a synthetic tetrapeptide based on epithalamin, a hormone produced by the pineal gland. It has been studied primarily for its effects on telomerase activation — the enzyme that maintains telomere length at the ends of chromosomes. Telomere shortening is accelerated by oestrogen decline and oxidative stress, both of which increase during menopause. Research in cell culture and animal models has suggested that epitalon can reactivate telomerase in somatic cells and improve markers of cellular ageing, though robust human clinical trial data is limited.

Kisspeptin-10 plays a fundamental role in the hypothalamic control of reproductive hormones. During the menopausal transition, dysregulated kisspeptin signalling contributes to the erratic gonadotropin surges that cause hot flushes — the most characteristic menopausal symptom. Research has shown that kisspeptin neurons in the hypothalamus are directly involved in the thermoregulatory dysfunction underlying vasomotor symptoms. While kisspeptin-10 is primarily studied in the context of fertility treatment, understanding its role in menopausal physiology is an active area of investigation.

All three of these peptides remain research compounds and are not approved for the treatment of menopausal symptoms. Their inclusion here is for educational purposes only.

Osteoporosis is one of the most serious long-term consequences of menopause, driven by the loss of oestrogen's protective effect on bone remodelling. In the first 5–7 years after menopause, women can lose 2–5% of their bone density per year, significantly increasing fracture risk.

While no research peptide has been specifically validated for osteoporosis prevention in postmenopausal women, several peptides interact with pathways relevant to bone metabolism. Growth hormone stimulates IGF-1 production, which is a key mediator of osteoblast activity and bone formation. The age-related decline in GH/IGF-1 signalling contributes to reduced bone turnover and impaired bone quality. Theoretically, GH secretagogues like CJC-1295 and ipamorelin might support bone metabolism by restoring more youthful GH/IGF-1 levels, though clinical evidence for this specific application is lacking.

BPC-157 has shown effects on bone healing in animal fracture models, potentially through its angiogenic and growth factor-modulating properties. However, there is a significant difference between accelerating fracture healing and preventing osteoporotic bone loss, and BPC-157 should not be considered a treatment for osteoporosis.

The established medical approaches to postmenopausal bone health remain HRT, bisphosphonates, denosumab, and romosozumab (a monoclonal antibody, not a peptide), alongside adequate calcium and vitamin D intake, weight-bearing exercise, and fall prevention strategies. Any woman concerned about bone health should have a DEXA scan and discuss evidence-based prevention strategies with her healthcare provider.

For women over 50 considering peptide research, several safety considerations deserve particular attention.

Hormonal interactions: Postmenopausal women may be taking HRT, thyroid medication, or other hormonal therapies. Peptides that modulate the endocrine system (particularly GH secretagogues and kisspeptin) could potentially interact with these treatments. Any peptide use should be discussed with the prescribing physician to avoid unintended hormonal effects.

Cancer screening: Many peptides have growth-promoting properties — they stimulate cell proliferation, angiogenesis, or tissue repair. While these properties are desirable in the context of healing and regeneration, they raise theoretical concerns in individuals with undetected malignancies. Postmenopausal women should be up to date with breast cancer screening (mammography), cervical screening, and bowel cancer screening before considering any growth-promoting peptide.

Cardiovascular risk: Cardiovascular disease becomes the leading cause of death in women after menopause. Peptides affecting metabolic parameters — including GH secretagogues (which can influence insulin sensitivity) and GLP-1 agonists (which have cardiovascular benefits) — should be evaluated in the context of the individual's cardiovascular risk profile.

Kidney and liver function: Age-related decline in renal and hepatic function can affect peptide metabolism and clearance. Postmenopausal women, particularly those over 60, should ensure that their kidney and liver function are assessed before using any peptide.

The most important message for women navigating menopause is that evidence-based medical care should be the foundation of any management plan. Peptides may be of interest as an area of scientific research, but they should not replace proven treatments such as HRT, lifestyle interventions, and established pharmaceutical therapies. This content is for educational purposes only and does not constitute medical advice.